Quent Capital LLC Sells 3,008 Shares of Natera, Inc. (NASDAQ:NTRA)

Quent Capital LLC decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 94.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 175 shares of the medical research company's stock after selling 3,008 shares during the period. Quent Capital LLC's holdings in Natera were worth $28,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in NTRA. Blue Trust Inc. grew its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc boosted its stake in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after purchasing an additional 166 shares during the period. Covestor Ltd grew its holdings in Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after buying an additional 95 shares during the last quarter. GAMMA Investing LLC increased its position in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock worth $55,000 after buying an additional 106 shares during the period. Finally, True Wealth Design LLC acquired a new position in shares of Natera during the third quarter worth approximately $57,000. 99.90% of the stock is owned by institutional investors.

Insider Buying and Selling at Natera

In other news, insider John Fesko sold 663 shares of the business's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the transaction, the insider now directly owns 156,044 shares of the company's stock, valued at $27,739,941.88. The trade was a 0.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Burkes Brophy sold 43,502 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $176.88, for a total value of $7,694,633.76. Following the sale, the chief financial officer now owns 70,629 shares in the company, valued at approximately $12,492,857.52. This trade represents a 38.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 305,454 shares of company stock worth $51,290,625 over the last ninety days. Corporate insiders own 7.60% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on NTRA shares. Sanford C. Bernstein raised their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, January 10th. Robert W. Baird raised their price target on shares of Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. StockNews.com lowered shares of Natera from a "hold" rating to a "sell" rating in a research report on Thursday, November 14th. Barclays assumed coverage on Natera in a research report on Thursday, January 23rd. They set an "overweight" rating and a $200.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their price target on Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, Natera has an average rating of "Moderate Buy" and an average target price of $165.88.

Natera Price Performance

Shares of NTRA traded up $2.66 during trading hours on Monday, hitting $173.39. The stock had a trading volume of 1,571,626 shares, compared to its average volume of 1,326,767. The stock has a market capitalization of $22.89 billion, a price-to-earnings ratio of -98.52 and a beta of 1.66. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company's fifty day moving average is $167.86 and its two-hundred day moving average is $143.93. Natera, Inc. has a 52 week low of $68.03 and a 52 week high of $183.00.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.